Reliability, feasibility and validity of a novel digital monitoring platform assessing cognitive and motor symptoms in people with Stage I and II Huntington’s disease (HD)
Objective: To determine the reliability and convergent validity of a novel digital monitoring platform offering objective, daily assessment of cognitive and motor symptom severity in…Digital monitoring of Huntington’s disease with smartphone and smartwatch wearable technology: The Digital-HD study
Objective: To investigate the tolerability and feasibility of using wearable smartphone and smartwatch technologies to monitor the motor, behavioural, cognitive and quality of life (QoL)…Composite UHDRS shows extensive spatial correlation with grey matter and white matter volume in Huntington’s disease gene carriers
Objective: This work sought to determine the structural correlates of variability in cUHDRS in HD gene expansion carriers (HDGC). Background: Symbol digit modalities test (SDMT),…Grey-matter volume changes underpinning irritability and aggression in early manifest Huntington’s disease
Objective: To explore grey-matter volume (GMV) differences between early-stage Huntington's disease (HD) patients with and without significant irritability/aggression symptoms (IAs) and to assess it association…Involuntary movements with abnormal brain imaging: A Case Report
Objective: To present a case of juvenile-onset Huntington's disease (HD) with a mixed phenotype and abnormal brain imaging. Background: HD is an autosomal-dominant neurodegenerative disorder…A Unified Staging System for Prodromal and Manifest Huntington’s disease
Objective: To develop an integrated staging methodology for Prodromal and Manifest Huntington’s disease (HD). Background: Once HD is diagnosed clinically (also known as, motor-onset/manifest), HD…Ancillary Service Utilization and Impact in Huntington’s Disease
Objective: To determine which Huntington’s disease (HD) patient characteristics correlate with ancillary service utilization. To examine the longitudinal impact of ancillary therapies on clinical characteristics.…Seeking regulatory feedback on novel clinical outcome assessments: a case example from the Huntington’s Disease – Regulatory Science Consortium (HD-RSC)
Objective: To align with regulators on the utility and development strategy of novel clinical outcome assessments for use in Huntington’s disease (HD) clinical trials. Background:…Motor assessments in HD clinical trials: Q-Motor versus the UHDRS-TMS – what did we learn from recent studies?
Objective: To review the performance of UHDRS-TMS and Q-Motor quantitative motor measures in recent placebo-controlled clinical trials. Background: The UHDRS-TMS has widely been used to…Huntington’s disease: A case review of Sub-Saharan Africans with diverse origins
Objective: To characterise the Huntingtons disease phenotype in Sub-saharan Africans. Background: Huntington’s disease (HD) is a debilitating neurodegenerative illness that leads to diminished cognitive function,…
- « Previous Page
- 1
- …
- 18
- 19
- 20
- 21
- 22
- 23
- Next Page »